Last Updated: November 24, 2023


Featured Articles

Drug Pricing Advisory Boards: What They Are and Why They Matter to Patients

HIV/HCV Watch | July 2023

Long-Acting, Injected HIV Meds Can Help Tough-to-Treat Patients | July 5, 2023

2023 Treatment Guide: Dealing With HIV Med Side Effects? | July 3, 2023

Updates to HIV Clinical Guidelines on Prevention and Treatment of Opportunistic Infections | June 28, 2023

A Treatment Timeline

POZ Magazine | January 17, 2023

Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV 

Gilead | December 22, 2022

FDA Approves SUNENCA (lenacapavir) for Adults with Limited Treatment Options

FDA | December 22, 2022

Blue Cross and Blue Shield Accused of Placing Most HIV Drugs into Highest Tiers

POZ | December 8, 2022

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel

JAMA. 2022; doi:10.1001/jama.2022.22246. [epublished online December 1, 2022]

Exciting alternatives: An overview of long-acting HIV treatment, prevention

Healio | October 2022

American Academy of HIV Medicine Launches Long-Acting Agent Resource Center

American Academy of HIV Medicine | August 22, 2022

Long-acting Agent Resource Center website

HIV LAA | August 2022

2022 HIV Drug Chart

POZ | June 27, 2022

12 Surprisingly Interesting Facts About Making Medicines And The Pharma Industry

Sintered Filter | May 10, 2022

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV | January 20, 2022

Updates in the Pipeline of HIV Therapy

Infectious Disease Special Edition | January 14, 2022

News Updates

Considerations for long-acting antiretroviral therapy in older persons with HIV 

AIDS. 2023 Dec 1;37(15):2271-2286. doi: 10.1097/QAD.0000000000003704. Epub 2023 Nov 16.

NIH Statement on Preliminary Efficacy Results of First-in-Class Gonorrhea Antibiotic | November 14, 2023

Risk Factors for Dolutegravir Resistance Identified in Patients With HIV

Infectious Disease Advisor | November 14, 2023

HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis

The Lancet | November 2023

Quality of Life of People Living with HIV on Antiretroviral Therapy

Dove Medical Press | November 10, 2023

Commercial Determinants of Access to HIV Preexposure Prophylaxis

JAMA | November 10, 2023

Rukobia Still Effective at Five Years for People With Drug-Resistant HIV

POZ Magazine | November 8, 2023

Implementation of Long-Acting Drugs for Treatment and Prevention of HIV

IAS-USA | November 2023

Trial Shows Limited Resistance to Sunlenca in Patients with HIV 

Managed Healthcare Executive | October 23, 2023

2 Year Data on Lenacapavir Reinforces Clinical Profile for Adults With Multi-Drug Resistant HIV 

Contagion Live | October 21, 2023

Single High-Dose Liposomal Amphotericin B Safe for HIV-Associated Fungal Infections

Infectious Disease Advisor | October 19, 2023

IDWeek 2023: New Data Provide Closer Look at Real-World Utilization of Cabotegravir for HIV PrEP 

Patient Care Online | October 15, 2023

Pre-Exposure Prophylaxis | September 28, 2023

Another class of cancer drugs may contribute to curing HIV

Aidsmap | September 18, 2023

Observations from ID and Beyond: Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy — Time to Change Treatment Guidelines?

NEJM | September 25, 2023

Clinicians Weigh In on the Benefits of Rapid Antiretroviral Therapy for HIV in EDs

Infectious Disease Advisor | September 22, 2023

Can a Shot to Prevent HIV Make a Dent in America’s Epidemic?

US News | September 21, 2023

Doxycycline Improves Outcomes of Early Syphilis in Patients With HIV 

Infectious Disease Advisor | September 20, 2023

Two-drug antiretroviral regimens for HIV

The BMJ | September 1, 2023

Lenacapavir: Drug Offers New Hope for Multi-drug Resistant HIV

Yale School of Medicine - Yale University | August 30, 2023

HIV Virologic Suppression Maintained After Switch to Long-Acting ART 

Infectious Disease Advisor | August 30, 2023

Overcoming HIV Drug-Resistance Mechanisms

Infectious Disease Special Edition | August 18, 2023

MSF refuses to sign ViiV's last-minute NDA for access to most-effective HIV prevention drug CAB-LA 

MSF Access Campaign | August 17, 2023

PrEP use and HIV incidence among youth at-risk for HIV infection in Los Angeles and New Orleans: Findings from ATN 149 

J Acquir Immune Defic Syndr. 2023 Aug 14. doi: 10.1097/QAI.0000000000003272.

Switch to Dolutegravir/Lamivudine Works Well Despite Resistance Mutations

POZ Magazine | August 11, 2023

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and...

NIH | August 8, 2023

Immune-modulating medication may help clear HIV reservoir

Aidsmap | August 5, 2023

More Time on Dolutegravir Needed Before Drug Switch: Study

Medscape | August 4, 2023

Not 'if' but 'when': Antibiotic resistance poses existential threat for modern medicine | July 30, 2023

Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis 

NIH | July 27, 2023

How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy

The New York Times | July 22, 2023

Walmart Opens 70 More HIV-Focused Pharmacies

POZ Magazine | July 7, 2023

USFDA gives tentative approval to Lupin's HIV/AIDS drug

The Financial Express | July 4, 2023

Gilead prevails in $3.6 billion antitrust trial over HIV meds

Courthouse News Service | June 30, 2023

The HIV-1 capsid core is an opportunistic nuclear import receptor

Nature Communications | June 24, 2023

Second-Line Switch to Dolutegravir for Treatment of HIV Infection

New England Journal of Medicine | June 2023

What happens to HIV drugs in the body, and do missed doses matter?

Aidsmap | June 2023

Real-world data confirm the efficacy of dolutegravir-based dual therapy

Aidsmap | May 29, 2023

Interest Grows in Long-Acting Injectables for HIV Treatment

Pharmacy Times | March 17, 2023

Implementing Long-acting Injectable PrEP with an Eye Toward Equity: Yale's Dr. LaRon ... | March 2, 2023

New HIV Treatment and PrEP Guidelines

POZ Magazine | February 13, 2023

Sunlenca Looks Great for Highly Drug-Resistant HIV. Will It Serve a Broader Purpose? 

TheBody | January 31, 2023

Baseline Resistance to Second-Generation INSTIs, First-Line NRTIs Unlikely in HIV 

Infectious Disease Advisor | January 30, 2023

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial 

Lancet HIV. 2023 Jan;10(1):e15-e23. doi: 10.1016/S2352-3018(22)00291-0.

FDA approves Sunlenca for treatment-resistant HIV

Medical Xpress | December 29, 2022

Treatment of ocular-involving monkeypox virus with topical trifluridine and oral tecovirimat in the 2022 monkeypox virus outbreak 

Am J Ophthalmol Case Rep. 2022 Dec 13;101779. doi: 10.1016/j.ajoc.2022.101779.

High-Resistance Therapy Options for Treatment-Naïve Patients With HIV

ContagionLive | December 9, 2022

Antiretroviral Drugs for HIV Clinical Practice Guidelines (IAS,2022)

Medscape | December 9, 2022

Do Antidepressants Make HIV Meds Less Effective?

Plus Magazine | December 9, 2022

First clinical trial of possible HIV vaccine shows promising results | December 8, 2022

Toolkit: Long-Acting Injectables in HIV Treatment

TargetHIV | November 15, 2022

Fostemsavir Plus Optimized Background Therapy May Be Viable for MDR HIV

Dolutegravir Effectively Suppresses HIV in Pregnant Women

Contagion Live | November 2, 2022

FDA reports shortages of amoxicillin (November 1, 2022)

The Hill | November 1, 2022

HepB-CpG Vaccination Achieves Maximum Seroprotection in Patients With HIV 

Infectious Disease Advisor | October 28, 2022

Tybost (Cobicistat) - Oral: Uses, Side Effects, Dosages, Interactions

Verywell Health | October 28, 2022

European Medicines Agency Validates Viiv Healthcare's Marketing Authorisation Application For Cabotegravir Long-Acting Injectable For HIV Prevention

ViiV Healthcare | October 28, 2022

Gilead's latest Biktarvy data offers hope to HIV patients

PMLiVE | October 25, 2022

A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection 

Retrovirology. 2022 Oct 22;19(1):22. doi: 10.1186/s12977-022-00608-1.

Tolerability Drives Most ART Switch Decisions in Patients Living With HIV/AIDS 

Contagion Live | October 21, 2022

Long-Term Biktarvy Resulted in High Rates of Viral Suppression 

Infectious Disease Special Edition | October 20, 2022


  2019 Archives 2020 Archives 2021 Archives 2022 Archives